A5040135202- Hematopoietic Stem Cell Transplantation
- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Hemoglobinopathies and Related Disorders
- Acute Myeloid Leukemia Research
- Chronic Lymphocytic Leukemia Research
- Immune Cell Function and Interaction
- Viral-associated cancers and disorders
- Blood groups and transfusion
- Viral Infectious Diseases and Gene Expression in Insects
- Cutaneous lymphoproliferative disorders research
- Cancer, Lipids, and Metabolism
- Acute Lymphoblastic Leukemia research
- Monoclonal and Polyclonal Antibodies Research
- Protein Degradation and Inhibitors
- Multiple Myeloma Research and Treatments
- Neutropenia and Cancer Infections
- T-cell and B-cell Immunology
- Prenatal Screening and Diagnostics
- CNS Lymphoma Diagnosis and Treatment
- Inflammatory Biomarkers in Disease Prognosis
- Corneal surgery and disorders
- Cancer Genomics and Diagnostics
- Management of metastatic bone disease
- Kruppel-like factors research
Washington University in St. Louis
2009-2024
Albert Einstein College of Medicine
2023
The Ohio State University
2023
Rabin Medical Center
2023
Montefiore Medical Center
2023
Montefiore Einstein Comprehensive Cancer Center
2023
Centre Hospitalier Universitaire de Montpellier
2023
Manipal Academy of Higher Education
2021
Kasturba Medical College, Manipal
2021
Vanderbilt University Medical Center
1996-2021
Axicabtagene ciloleucel (axi-cel) is an autologous CD19 chimeric antigen receptor (CAR) T-cell therapy that approved for the treatment of relapsed or refractory large B-cell lymphoma. Little known about long-term survivorship after CAR therapy.
Abstract Helicobacter pylori–induced gastritis is the strongest singular risk factor for gastric adenocarcinoma. Matrix metalloproteinase-7 (MMP-7) a proteolytic enzyme that can modify intestinal microbial replicative niche as well affect tumorigenesis, and H. pylori stimulates expression of MMP-7 in epithelial cells vitro. Utilizing transgenic murine model pylori–mediated injury, our experiments now show inflammation increased within context deficiency, which involves both Th1-...
Off-the-shelf immunotherapeutics that suppress tumor growth and provide durable protection against relapse could enhance cancer treatment. We report preclinical studies on a CD33 x CD3 bivalent bispecific diabody, AMV564, not only suppresses growth, but also facilitates memory responses in mouse model of acute myelogenous leukemia (AML). Mechanistically, single 5-day treatment with AMV564 seems to reduce burden by redirection T cells, providing time window for allogeneic or other cells...
With the advent of widespread tumor genetic profiling, an increased number mutations with unknown significance are being identified. Often, a glut uninterpretable findings may confuse clinician and provide little or inappropriate guidance in therapeutic decision-making. This report describes method protein modeling by silico analysis (ie, using computer simulation) that is easily accessible to practicing without need for further laboratory analysis, which can potentially serve as guide...
IntroductionPost-transplant cyclophosphamide (PTCy) enables blood and marrow transplantation (BMT) across the HLA barrier. BMT for transfusion dependent thalassemia (TDT) is restricted due to limited donor availability, graft rejection, regimen-related toxicity. We explored use of non-myeloablative (NMA) allogeneic using best available with PTCy in setting a collaborative consortium improve engraftment estimate transplant-related mortality (TRM) event-free survival.MethodsA multicenter...
Haploidentical bone marrow transplant (haplo-BMT) offers near universal donor availability as a curative modality for individuals with severe sickle cell disease (SCD). However, the required intense immunodepletion is associated increased infectious complications. A paucity of data exists on immune reconstitution following haplo-BMT SCD.A multi-institution learning collaborative was developed in context phase II clinical trial non-myeloablative, related post-transplant cyclophosphamide SCD....
IntroductionHaploidentical bone marrow transplant (haplo-BMT) with post-transplant cyclophosphamide (PTCy) has increased curative options for patients sickle cell disease (SCD), near universal donor availability. However, this approach is associated risk of graft failure, delayed engraftment, and early viral reactivation. Limited knowledge exists regarding immune reconstitution (IR) following haplo-BMT. We hypothesized that the immunomodulatory properties pre-transplant conditioning PTCy...
Primary dural marginal zone lymphomas (MZLs) are exceptionally rare, with fewer than 100 cases reported to date. While the association between hepatitis C virus (HCV) infection and lymphoma is well established, it unclear if this extends all anatomic sites. Here we report a case of MZL in 61-year-old woman an HCV infection. To our knowledge, first associated immunocompetent patient was successfully treated radiotherapy rituximab. As such, future primary found dura should prompt consideration...
TPS7100 Background: Despite the promising efficacy of CAR-T for patients with relapsed or refractory (R/R) large B-cell lymphomas (LBCL), more than 60% will relapse, majority which occur in first 6 months. Approximately 30% LBCL treated achieve a partial response (PR) on day 30 (D30) PET-CT assessment. Of D30 PR, 70% eventually progress, yet standard care remains close observation. Early consolidative treatment strategies utilizing therapies different mechanism action may improve outcomes,...